{"filings":[{"id":92839,"accession_number":"0001434647-26-000029","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.","Completed $50M sale of SDX portfolio to Commave Therapeutics; prepaid $63.1M term loan, now debt-free.","Net income of $37.9M ($0.60 diluted) includes $43.3M one-time gain; adjusted net income $11.5M ($0.18 diluted).","Cash, equivalents and securities $236.8M as of March 31, 2026; no near-term capital market dependency.","Enrolled 62 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome; FDA meeting expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":36220000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104013,"accession_number":"0001434647-26-000015","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.","Litigation with Commave in Delaware Chancery dismissed with prejudice; both parties release all claims.","Repaid $63M term loan (incl. $3M PIK interest) in full, terminating Credit Agreement and all liens.","CEO Neil McFarlane highlights debt-free balance sheet and enhanced financial flexibility.","Commave receives worldwide royalty-free perpetual license to SDX patents retained by Zevra."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104012,"accession_number":"0001434647-26-000009","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.","FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.","MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.","Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.","Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120289,"accession_number":"0001434647-25-000018","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zevra appoints Timothy Sangiovanni as interim CFO effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Sangiovanni named interim principal financial officer, effective January 1, 2026.","Sangiovanni currently serves as SVP Finance and Corporate Controller; joined company in 2015.","No change in compensation arrangements in connection with the appointment.","No information provided on predecessor's departure or timing of permanent CFO search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120288,"accession_number":"0001434647-25-000015","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra appoints Alicia Secor to board; director Wendy Dixon retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Wendy Dixon resigned effective Dec 2, 2025; no disagreement with company operations.","Alicia Secor appointed to board as Class I director, term expiring at 2028 annual meeting.","Secor will serve on Compensation and Audit committees; compensation per director policy.","Secor brings 30+ years life sciences experience, including CEO roles at Atalanta and Juniper."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120287,"accession_number":"0001193125-25-289865","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.","Separation benefits: 12 months base salary, 40% annual bonus, COBRA, full equity vesting.","Company has initiated search for new CFO; Neil F. McFarlane thanked Clifton for his leadership.","Clifton played role in company's transition from development to commercial-stage rare disease firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120286,"accession_number":"0001434647-25-000009","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.","Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.","MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.","Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.","Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":72345000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136874,"accession_number":"0001628280-25-039883","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.","Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.","Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.","Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.","MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":46282000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154102,"accession_number":"0001193125-25-130714","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zevra Therapeutics stockholders elect Dixon and Favorito as Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wendy Dixon elected with 25.8M for (9.1M withheld); Tamara Favorito with 25.6M for (9.3M withheld). Broker non-votes ~9.65M.","Dissident Mangless failed to comply with Rule 14a-19 and bylaws; his nominees Mickle and Regan disregarded despite 9.2M and 8.4M votes.","Ratification of Ernst & Young as auditor passed: 43.8M for, 360k against, 382k abstain; no broker non-votes.","81.4% of outstanding shares (44.5M of 54.7M) were present or represented at the May 29, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154101,"accession_number":"0001437749-25-016452","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.","Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.","Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.","Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.","MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives."],"consensus_eps_estimate":0.0824,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":20401000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154100,"accession_number":"0001193125-25-073991","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["2.01","2.02","8.01","9.01"],"status":"ready","headline":"Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.","PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.","Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.","Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172714,"accession_number":"0001437749-25-007032","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.","Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.","Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.","MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.","OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172713,"accession_number":"0001193125-25-037619","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.","PRV granted in Sep 2024 upon FDA approval of MIPLYFFA for Niemann-Pick type C.","Transaction subject to HSR waiting period expiration; Cantor Fitzgerald advised.","CFO states non-dilutive capital strengthens balance sheet, supports commercial launches and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189734,"accession_number":"0001437749-24-036876","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.","Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.","Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.","In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.","Changes include elimination of positions in CMC and Clinical Development as part of strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189733,"accession_number":"0001437749-24-035988","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.","Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.","Indicated in combination with miglustat for neurological NPC in patients aged 2+.","AmplifyAssist patient support program launched to address insurance and access barriers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189732,"accession_number":"0001437749-24-034565","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.","FDA approved MIPLYFFA (arimoclomol) on Sept. 20 for Niemann-Pick type C; first-ever NPC drug approved.","Cash, equivalents, and investments $95.5M as of Sept. 30; cash runway forecast into 2027, excluding PRV sale.","Completed $64.5M public offering of 10.6M shares at $6.50; closed Iowa/Virginia labs, outsources early R&D.","OLPRUVA revenue minimal; 90 prescription enrollment forms for MIPLYFFA received by Oct. 31, 30% approved for reimbursement."],"consensus_eps_estimate":-0.0357,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":11569000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206243,"accession_number":"0001437749-24-029747","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra Therapeutics' MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease type C","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved MIPLYFFA (arimoclomol) for NPC in adult and pediatric patients 2 years+; first FDA-approved NPC treatment.","MIPLYFFA is indicated for use in combination with miglustat for neurological manifestations of NPC.","Zevra received a rare pediatric disease priority review voucher (PRV) with the approval.","Launch of AmplifyAssist patient support program; MIPLYFFA expected commercially available in 8-12 weeks.","Conference call and webcast on Sept 23, 2024 at 8 a.m. ET to discuss approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206242,"accession_number":"0001437749-24-026397","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.","FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.","Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.","OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.","Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M."],"consensus_eps_estimate":1.5278,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7874000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206241,"accession_number":"0001193125-24-197943","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.","Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.","Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.","Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206240,"accession_number":"0001193125-24-196961","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.","Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.","Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.","Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.","The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements."],"consensus_eps_estimate":1.5278,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7874000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206239,"accession_number":"0001437749-24-024543","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA panel votes 11-5 that Zevra's arimoclomol is effective for NPC; PDUFA date Sep 21","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA GeMDAC voted 11 yes, 5 no that data support arimoclomol as effective for Niemann-Pick disease type C.","PDUFA action date for arimoclomol NDA is September 21, 2024.","The committee’s recommendation is non-binding but will be considered by the FDA.","Vote based on pivotal trial, long-term open-label extension, and expanded access program data.","Zevra CEO expresses confidence in arimoclomol's clinical benefit and path to approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206238,"accession_number":"0001437749-24-022668","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Zevra Therapeutics enters $75M at-the-market equity distribution agreement with Citizens JMP Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows sale of up to $75M in common stock at company's discretion.","Sales agent receives 3% commission on gross proceeds; shares sold under existing shelf registration.","Prior equity distribution agreement with Citizens JMP and RBC Capital terminated effective July 12, 2024.","Company is not obligated to make any sales under the new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206237,"accession_number":"0001437749-24-022362","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.","Meeting scheduled for August 2, 2024; background materials released two business days prior.","PDUFA action date for arimoclomol is September 21, 2024.","Arimoclomol is an orally delivered, first-in-class treatment for NPC, a rare genetic disease.","Zevra CEO highlights opportunity for NPC community to share treatment needs with the advisory committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223312,"accession_number":"0001437749-24-019074","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).","ESS decreased ~9 points after 5 weeks; at week 7: ESS -9.4 (QD), -8.8 (BID); IHSS -16.1 QD, -12.3 BID.","Sleep Inertia VAS decreased 25.9 (QD) and 17.2 (BID); Brain Fog Scale decreased 23.8 (QD) and 22.3 (BID).","PK data supports nighttime dosing; European Commission granted Orphan Drug Designation for KP1077 in IH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223311,"accession_number":"0001437749-24-016275","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.","Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.","Advisory say-on-pay vote approved (11.2M for, 9.9M against).","Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.","Approximately 74.5% of shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223310,"accession_number":"0001437749-24-015210","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.","Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.","OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.","Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.","Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3425000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":602970000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}